CXL Research Study
The prospective CXL research study evaluated the long-term results of corneal collagen cross-linking (CXL) with ultraviolet A irradiation and riboflavin in 32 patients (40 eyes) with grades I through III progressive keratoconus. At five years, CXL halted the disease’s progression, stabilized UCVA, refraction, corneal thickness, corneal power, and posterior elevation. Improvements were also noted in BCVA and anterior elevation. While one patient dropped out due to an increase in BCVA and an inability to tolerate contact lenses or spectacles, no safety issues were noted. Ophthalmology, August 2013
For more detailed information about this treatment, please visit www.cxlusa.com
Can CXL be Performed for Everyone with Keratoconus?
Investigators analyzed a group of 104 eyes to determine preoperative characteristics that may influence outcomes from CXL treatment. There was no factor that was independently predictive of CXL failure. The study did show that in general, eyes with worse CDVA and higher maximum K readings were more likely to improve. They concluded that all eyes should be considered for treatment with the goal of stabilizing the disease’s progression. Patients and physicians should be aware of the potential risk for loss of visual acuity. For more detailed information about this treatment, please visit www.cxlusa.com
Does Insurance Cover CXL Treatment?
Unfortunately, we have yet to see an insurance policy cover this treatment.
Is Financing Available?
Convenient, affordable financing is available to help our patients get the treatment they need before their keratoconus or another similar condition progresses to the point where they can no longer have CXL.
Financing With CareCredit
CareCredit® is a payment plan that fits your individual needs and financial circumstances. If you’ve been putting off having an ophthalmic procedure due to budget constraints, CareCredit® can help. Click here or call our office for details.